MARKET

IMNPQ

IMNPQ

Immune Pharmaceu
EXMKT

Real-time Quotes | Nasdaq Last Sale

0.0010
-0.0006
-37.50%
Closed 16:00 05/24 EDT
OPEN
--
PREV CLOSE
0.0016
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.062
52 WEEK LOW
0.0001
MARKET CAP
172.88K
P/E (TTM)
-0.0005
1D
5D
1M
3M
1Y
5Y
No Data
No Data
Learn about the latest financial forecast of IMNPQ. Analyze the recent business situations of Immune Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IMNPQ stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
High2.000
Average2.000
Low2.000
Current 0.0010
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 172.88M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
1
31.08K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
President/Chief Executive Officer
Adeel Ahmed-Daudpota
Chief Financial Officer
Devin Shaw
Controller
John Clark
Director
Anthony Fiorino
Director
Daniel Teper
Independent Director
John Neczesny
Independent Director
Jeffrey Paley
No Data
No Data
About IMNPQ
Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The Company’s oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Webull offers kinds of Immune Pharmaceuticals Inc stock information, including EXMKT:IMNPQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNPQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMNPQ stock methods without spending real money on the virtual paper trading platform.